1. Introduction {#sec1-ijms-21-03253}
===============

The first evidence of the regulatory function of microRNA (miRNA) was reported in *C. elegans* by Lee et al. three decades ago \[[@B1-ijms-21-03253]\]. Since this discovery, many examples of these small nucleotide chains were identified in different species, evidencing the existence of a post-transcriptional regulation mediated by RNA molecules and fairly conserved in diverse organisms \[[@B2-ijms-21-03253],[@B3-ijms-21-03253]\]. Numerous laboratories across the world have focused their research in identifying new miRNAs and having a full picture of their biological functions. Interestingly, the public ENCODE project revealed that around 70% of the human genome has biochemical activity, reinforcing the idea that non-coding DNA exceeds protein coding sequences and generating focus on regulatory nucleotides \[[@B4-ijms-21-03253]\]. Similarly to miRNAs, small interfering RNAs (siRNAs) are also noncoding RNAs with an important role in gene regulation \[[@B5-ijms-21-03253]\]. Both miRNAs and siRNAs are short RNA molecules that target messenger RNA (mRNA) and can exert gene silencing. However, siRNAs are very specific with only one mRNA target while miRNAs have multiple targets \[[@B5-ijms-21-03253]\]. Research on siRNA clinical applications has advanced ahead of miRNAs because they are effective in gene silencing and they could involve less potential off-target effects because of this one single target \[[@B6-ijms-21-03253]\]. But, miRNA-based therapies can provide in addition to gene silencing (and elimination of undesired proteins) the restoration of missing proteins to physiological levels. Consequently, these therapies are challenging but also offer more therapeutic opportunities than siRNA-based drugs. For this reason, they are considered today the future of non-coding RNA treatments. In addition, they are currently being applied as quantifiable indicators of pathological states and as molecular biomarkers for early diagnosis. Regular protocols examine differences in the expression of miRNAs as prognostic markers between groups of patients, with and without medical treatments, searching for miRNA targets that can give information about the efficiency and effect of different therapies \[[@B7-ijms-21-03253],[@B8-ijms-21-03253]\]. Regarding the use of miRNAs as biomarker there are already clinical databases, such as the BACAP cohort for pancreatic cancer, that provide the opportunity to identify correlations between the presence/expression of a broad panel of miRNAs. Finally, for some diseases it has been possible to develop miRNA targeted treatments based on these clinical databases. The most advanced treatment in this sense is called miravirsen and it is based on a locked nucleic acid (LNA)-modified oligonucleotide targeting the liver expressed miR-122 for treatment of hepatitis C virus infection \[[@B9-ijms-21-03253],[@B10-ijms-21-03253]\].

miRNA-based treatments suffer for low stability and efficiency \[[@B11-ijms-21-03253]\] and they require chemical modifications \[[@B12-ijms-21-03253],[@B13-ijms-21-03253]\] or conjugation/encapsulation in different kinds of nanovectors such as lentivirus, polymeric nanoparticles, or exosomes \[[@B14-ijms-21-03253],[@B15-ijms-21-03253],[@B16-ijms-21-03253]\]. This review intends to highlight the interest of developing more advanced strategies for miRNA treatments; the challenges related with their stability, specificity, side-effects, and interest of their encapsulation within drug delivery carriers.

Specifically, we will illustrate why and how miRNAs could ameliorate the pathologies and complications of respiratory disease, with a special focus being given to the recent achievements in pulmonary hypertension (PH). PH involves a continuous remodeling of the pulmonary vasculature, that is similar to cancer in some aspects \[[@B17-ijms-21-03253]\], leading to muscularization of pulmonary vessels, development of vascular lesions, continuous vasoconstriction, and final heart failure. Current pharmacological therapies only target three pathways that either regulates the vasodilatory/vasoconstriction balance (prostacyclin and endothelin pathway) or the uncontrolled cell proliferation (nitric oxide pathway) \[[@B18-ijms-21-03253]\]. As a result, of these therapies patients can only improve their life quality but not without suffering adverse side effects. This fatal lung disease lacks effective treatments. Therefore, there are compelling reasons to find new molecular targets and novel therapies that reverse the development of the disease. In this context, miRNA-based therapies have shown promising results that we will provide in the following sections while explaining the important role that had played their nanoencapsulation \[[@B19-ijms-21-03253]\].

2. Brief Description of miRNA Biogenesis {#sec2-ijms-21-03253}
========================================

To understand the therapeutic strategies based on miRNA, it is important to keep in mind the biological processes required for the biogenesis of mature, functional, and single stranded miRNA shown in [Figure 1](#ijms-21-03253-f001){ref-type="fig"}. Only this mature molecule will be capable of achieving gene silencing through partial complementarity with its target mRNA. miRNA biogenesis involves several biological processes where the correct action of auxiliary factors is crucial but their degree of influence is still under discussion \[[@B20-ijms-21-03253]\]. Discrepancies have been found between species \[[@B21-ijms-21-03253]\], and some authors refer to two pathways \[[@B22-ijms-21-03253]\], but here for the sake of simplicity we have condensed the miRNA maturation process in general terms. [Figure 1](#ijms-21-03253-f001){ref-type="fig"} attempts to summarize the complex miRNA biogenesis in eukaryotic cells. First, often RNA polymerase III, in the cellular nucleus, transcribes specific DNA sequences, giving rise to long stem-loop structures called pri-miRNA. pri-miRNA has often well conserved terminal loops where auxiliary factors bind to ensure an optimal pri-miRNA processing. One of these factors is hnRNP, an RNA-binding protein that acts by binding the loop of the pri-miRNA to produce a relaxation at the stem \[[@B23-ijms-21-03253],[@B24-ijms-21-03253]\]. Subsequently, Drosha, a RNase-III type enzyme, binds the microprocessor complex DGCR8 and cleaves the nucleic acid to form pre-microRNA, a 60--80 base pairs chain with typical hairpin conformation. After that, the protein Exportin-5 (and probably through alternative modes of transport) is responsible for transporting the pre-miRNA to the cytosol through nuclear pores where it will be further processed until becoming mature and functional \[[@B25-ijms-21-03253]\]. In this compartment, it is cleaved by Dicer, creating microRNA duplexes. These duplex RNAs bind the protein Argonaute (AGO) which is implicated in the separation of the double chain and form the RNA-induced silencing complex (RISC). Finally, the guide strand remains anchored to the complex to fulfil its duty while the passenger strand is decomposed in some cases but it can also stay being functional. Generally, the strand with the less stably paired 5ʹ-end is selected as the mature miRNA. Argonauts are composed of three domains, PAZ, MID, and PIWI. In humans, four isoforms have been found. Recent studies point to the mechanism by which miRNA exerts its action softly differs depending on the binding to the AGO isoform \[[@B11-ijms-21-03253]\].

miRNA-based therapies target at least one of the multiple miRNA biogenesis pathways which gives an idea about the variety of possible therapies. In [Figure 1](#ijms-21-03253-f001){ref-type="fig"} we have only highlighted miRNAs that can be administered in therapies based on replacement by exogenous nucleic acids and there are already four. If we consider that these four possibilities can be synthesized with different chemical modifications, the options for building novel drugs exponentially increase. In the following sections we will try to give a short overview of the recent and more successful (up to now) therapeutic strategies.

3. Key Features of miRNA-Based Medical Applications {#sec3-ijms-21-03253}
===================================================

miRNAs largely influence homeostasis and their abnormal expression can be related to various diseases although their complete mode of action is not yet understood. In principle, miRNA exerts their function by canonically pairing their cognate mRNA. For the target recognition, a mature miRNA has "seed regions," short sequences extending from bases 2 to 8 on the tail of the mature miRNA strand on the 5' end that bind the targeted mRNA as shown in [Figure 2](#ijms-21-03253-f002){ref-type="fig"}.

These segments match a complementary sequence of the 3' untranslated region (UTR) of the mRNA, 5' UTR or within the mRNA coding sequence. The union of the miRNA to the mRNA promotes this oligonucleotide destruction, downregulating the expression of their codified protein. This inhibits the protein synthesis \[[@B26-ijms-21-03253]\]. However, the regulation of the gene expression can be accomplished through different genetic and epigenetic mechanisms. The method of choice varies depending on complementarity. If the miRNA matches perfectly to the target mRNA the interference pathway is activated and the mRNA degraded. But, in the case that the base pairing is incomplete, miRNA hybridize partially to the cognate region of the mRNA, forcing the repression of the protein translation \[[@B27-ijms-21-03253]\]. In addition to these functions, miRNA has been found to be involved in chromatin modification and in the methylation pathway \[[@B28-ijms-21-03253],[@B29-ijms-21-03253]\]. There is a general consensus on the lack of full knowledge about all mechanisms for gene silencing and biological functions of miRNAs and there is a constant release of new information about novel roles of these molecules in human disease \[[@B30-ijms-21-03253]\].

Because of the difficulties to establish the precise mode of action of a particular miRNA, mathematical tools have been proposed to discriminate between processes in order to make a practical use of all obtained information toward clinical application \[[@B31-ijms-21-03253],[@B32-ijms-21-03253]\]. In this line, using a theoretical base and computational tools, a system biology approach which combines data-driven modelling and model-driven experiments has been suggested as an efficient method to better understand the regulatory role of miRNAs in coordinating gene expression \[[@B33-ijms-21-03253]\]. This work also underscored the idea that mathematical modelling is necessary for a deep understanding of miRNA's biological role and highlighted the complexity of the miRNA regulation. This becomes even more important when we take into account that there is a large amount of miRNAs that have not been discovered yet. More than 1 × 10^11^ potential combinations of different miRNAs can be generated with a sequence of only 20 nucleotides. In contrast, only less than 2000 different matured human miRNAs have been identified to date \[[@B34-ijms-21-03253]\].

The large amounts of miRNAs holding key biological roles, summed to the coincidences detected between the different species, seems to point out that these molecules are greatly selected and evolutionarily conserved. Thus, the translation of findings from preclinical models is more prospective than other molecular targets. miRNAs serve as biomarkers of disease progression and are targets for therapeutic intervention \[[@B26-ijms-21-03253]\]. Regular protocols for biomarkers selection examine the differences in the expression of these molecules between groups of individuals in search for syndrome targets and evaluation of the effect of therapies.

Some of the investigated disorders are: heart failure \[[@B35-ijms-21-03253]\], pancreatic cancer \[[@B36-ijms-21-03253]\], hepatitis B \[[@B37-ijms-21-03253]\], or asthma \[[@B38-ijms-21-03253]\]. Examples of therapies that have been examined using miRNAs as biomarkers are: Vandetanib for advanced medullary thyroid cancer \[[@B39-ijms-21-03253]\], oxaliplatin and capecitabine chemotherapy for advanced gastric \[[@B40-ijms-21-03253]\], tofacitinib treatment for rheumatoid arthritis \[[@B41-ijms-21-03253]\], pegylated interferon therapy for hepatitis B \[[@B10-ijms-21-03253]\], and adalimumab for early rheumatoid arthritis \[[@B42-ijms-21-03253]\].

4. Types of miRNA-Based Therapies {#sec4-ijms-21-03253}
=================================

The association of siRNAs and miRNAs with many diseases and their implication in modulating key aspects of gene silencing has brought these two molecules into the forefront of new therapeutic interventions \[[@B27-ijms-21-03253],[@B43-ijms-21-03253]\]. More than 20 clinical trials have been started in the last decade applying siRNA- and miRNA-based drugs for new therapeutics \[[@B44-ijms-21-03253]\]. The first siRNA medication, patisiran (commercialized as Onpattro in the USA), has been approved in 2018 by the FDA. miRNA-based therapies are less advanced but some are already in clinical trials such as miravirsen which is an inhibitor or miR-122 and many more that are in the preclinical stage \[[@B44-ijms-21-03253]\]. Although the modes of action of siRNAs and miRNAs are different both oligonucleotides are single stranded and form RISC complexes. Therefore, some of the strategies developed for an efficient siRNA drug delivery are being used to push the development of miRNA-based therapies.

All miRNA-based therapies present relevant advantages compared to other drug classes. First, they act fast and can alter gene expression of multiple transcripts at once \[[@B44-ijms-21-03253]\]. Moreover, the fact that these are endogenous compounds decreases their reactivity and immunogenic responses. miRNA and their targets are conserved and highly specific, diminishing adverse effects. Finally, miRNA can specifically suppress the translation of any gene, including intracellular targets. They can modulate drug targets that are inaccessible by conventional small molecule inhibitors and antibody based-therapies \[[@B45-ijms-21-03253]\].

However, the expected clinical success was not achieved until recently after the major hurdles of these therapies were overcome. These major issues included: (a) Inefficient binding affinity for complementary sequences, (b) inefficient pharmacokinetics and sub-optimal biodistribution, (c) low cell membrane penetration, and (d) enzymatic degradation by nucleases in vivo \[[@B46-ijms-21-03253]\]. Many miRNA-based therapies are synthetic oligonucleotides, chemically modified to enhance their stability, tissue targeting, uptake efficacy and binding affinity \[[@B46-ijms-21-03253],[@B47-ijms-21-03253]\]. In addition, they are encoded as prodrugs, in order to protect the active substance from the degradation mechanisms of exogenous genetic material that exist in eukaryotic cells \[[@B48-ijms-21-03253]\].

The most common modifications within the miRNA chain are led first to resist degradation by RNA nucleases and slow their removal in vivo by the liver. These chemical modifications alter the internucleotide connections or replace backbone phosphodiester for phosphorothioate, boranophosphate or peptide bonds. miRNAs can be also modified to improve cell and tissue targeting by decorating miRNAs with receptor-mediated endocytosis pathways. On the other hand, cell uptake can be improved by incorporating, at the 3' end, lipids or cholesterol which increases the permeability through the cellular lipid bilayer. Chemical functionalization with pH sensitive motifs have also been incorporated to synthetic miRNAs, typically internalized by cells in endosomal compartments, to escape and reach the cytosol where they exert gene silencing. The strategies to chemically modify oligonucleotides have been the subject of many recent reviews and debates about their influence on the pharmacological properties or miRNA-based therapies since often they reduce their efficiency \[[@B46-ijms-21-03253],[@B47-ijms-21-03253]\].

In 1997, the first chemical approximations of modified RNAs were reported by Takesi et al. They designed LNAs that are RNA analogues where the ribose residues are modified with an extra bridge that connects oxygen 2′ with carbon 4′ and paired specifically with their target miRNA \[[@B49-ijms-21-03253],[@B50-ijms-21-03253]\]. In 2005, Krutzfeldt et al. named a novel class of chemically engineered oligonucleotides "Antagomirs." These molecules were described as engineered siRNA with certain drug-like properties complementary to miRNA. They described a method to modify chemically single-stranded RNA analogues conjugated to cholesterol that was able to bind specific miRNA to achieve therapeutic silencing of an endogenous gene in vivo \[[@B51-ijms-21-03253]\]. A couple of years later, Wang et al. developed the miRNA mimic technology (miR-Mimic). With this approach is possible to generate double-stranded miRNA-like RNA fragments that can bind specifically to its target mRNA and produce posttranscriptional repression of the gene, mimicking an endogenous miRNA but acting as a gene-specific target \[[@B52-ijms-21-03253],[@B53-ijms-21-03253]\].

Because of the existence of different chemical strategies to restore the physiological levels of miRNAs it has been possible to establish three different kinds of miRNA-based therapies (that can be administered within nanoparticles or bare):

\(a\) Replacement therapies

In this case, the non-natural miRNA is the drug. Exogenous miRNAs are delivered into the organism to substitute underexpressed miRNAs ([Figure 1](#ijms-21-03253-f001){ref-type="fig"}). Theoretically, an artificial single stranded and mature miRNA could be used to replace the downregulated endogenous miRNA but this strategy has shown inefficient results probably because of the low stability of the molecule. Full length pri-mRNA has also been assayed as possible therapy but it was inefficient because pri-mRNA requires processing at the nucleus. Typically, the mimic miRNAs used in replacement therapies are duplex miRNAs or pre-miRNAs. Viral vectors are other kind of replacement strategies and probably the most efficient nanotherapies in transfecting cells though their application raises some safety concerns.

\(b\) Antisense-mediated inhibition therapies

Herein, the drug is an inhibitor called anti-miRNA of a specific and endogenous miRNA. These therapies intent to inhibit overexpressed miRNAs involved in pathogenic states of target diseases. The already mentioned LNAs or Antagomirs are examples of inhibition therapies. Miravirsen, the first LNA-based drug in clinical trials, antagonizes microRNA-122 which is a therapeutic target for the chronic hepatitis C virus infection \[[@B54-ijms-21-03253]\].

\(c\) Therapies based on influencing the auxiliary factors of miRNA biogenesis

These therapies, less popular than the two aforementioned, target the auxiliary factors of miRNA biogenesis such as the AGO proteins \[[@B55-ijms-21-03253]\]. Schmidt et al. developed miRNA-specific AGO2 protein inhibitors. They act both by antagonism to the active site of the enzyme and by blocking the short recognition sequence to the solvent-exposed target microRNAs seed region \[[@B56-ijms-21-03253]\].

5. Administration of miRNA-Based Therapies and the Relevant Contribution of Nanotechnology {#sec5-ijms-21-03253}
==========================================================================================

miRNA-based therapies are administered using diverse approaches. The simplest strategies are the local, systemic, or targeted administration of chemically modified miRNAs or anti-miRNAs \[[@B57-ijms-21-03253],[@B58-ijms-21-03253]\]. Despite considerable progress has been achieved with these three administration methods (i.e., enhanced bioactivity and decreased side effects) there are several issues to be addressed for a more extended clinical translation. One of them is the deficient ability of AGO proteins to recognize artificial miRNAs for the efficient formation of the silencing complex RISC. This is often due to the excessive chemical modifications incorporated into miRNA mimics. On the other hand, anti-miRNA-based therapies usually require a high dose in vivo which induces higher risk of negative side effects. Nevertheless, the most critical obstacle to be overcome is the inefficient biodistribution in vivo regarding cell uptake and organ-specific delivery. Thus, there is a great requirement to develop safe and efficient nanovectors for miRNA-based therapies and in particular for treating PH \[[@B59-ijms-21-03253],[@B60-ijms-21-03253]\]. [Figure 3](#ijms-21-03253-f003){ref-type="fig"} shows the schematic representation of some of the already used nanovectors for delivery of miRNA-based therapies.

5.1. Biological Delivery Nanovectors {#sec5dot1-ijms-21-03253}
------------------------------------

### 5.1.1. Virotherapy {#sec5dot1dot1-ijms-21-03253}

Virus-like nanovectors (e.g., adenovirus, lentivirus, etc.,) are extensively used for delivering miRNAs because they dispense miRNAs more efficiently than other carriers \[[@B61-ijms-21-03253],[@B62-ijms-21-03253],[@B63-ijms-21-03253]\]. They also permit the transduction of multiple miRNAs and their physicochemical properties can be partially modified by incorporating moieties such as the antifouling polymer polyethylene glycol (PEG) \[[@B64-ijms-21-03253]\].

However, it has been reported that they can induce mutagenic effects causing cancer and undesired immune responses which limits their clinical application, so their real translation into clinics is controvertible \[[@B65-ijms-21-03253]\].

### 5.1.2. Extracellular Vesicles and Nanocells {#sec5dot1dot2-ijms-21-03253}

In contrast, extracellular vesicles (EVs), considered as drug delivery carriers, are in ongoing clinical trials aiming to translate them from basic research to clinics. The main advantage of these nanovectors is that they can be obtained from patients avoiding toxicity \[[@B66-ijms-21-03253]\]. They are lipidic bilayer vesicles naturally released by cells which size varies from 10 to 10000 nm. EVs are often polydispersed in size and can be further functionalized with nanoparticles, for example for therapy \[[@B67-ijms-21-03253]\]. They are currently being used as successful drug delivery systems for miRNAs into particular cells \[[@B14-ijms-21-03253],[@B16-ijms-21-03253]\], such as hepatocytes or macrophages \[[@B68-ijms-21-03253]\]. Interestingly, they have been recently applied to demonstrate the therapeutic effect of miR-181a-5p/miR-324-5p against PH in vivo \[[@B19-ijms-21-03253]\]. They are supposed to have diminished side effects as compared to chemically engineered carriers because of their controllable origin. However, their exact composition is uncontrolled. They contain active molecules with unknown effects for the organism. Their properties are dependent upon their cellular origin and separation conditions which complicates the establishment of general protocols for their extraction, mass production, and characterization toward ensuring reproducibility and safety. These are the main challenges of this promising technology for miRNA delivery \[[@B69-ijms-21-03253]\]. Other very promising biological carriers for miRNAs (in clinical trials) are the bacterially derived EDV^TM^ nanocells (scheme 2 in [Figure 3](#ijms-21-03253-f003){ref-type="fig"}). In cancer, they have been able to carry and deliver efficiently miRNAs to tumors and stimulate the adaptive immune system augmenting their antitumoral response \[[@B8-ijms-21-03253]\]. These carriers are also biological lipidic bilayers with unknown effects on the body.

5.2. Engineered Synthetic Nanovectors {#sec5dot2-ijms-21-03253}
-------------------------------------

Synthetic nanovectors (schemes 3 to 7 in [Figure 3](#ijms-21-03253-f003){ref-type="fig"}) can be finely designed in the nanoscale and manufactured in a large scale owing to the advances achieved in nanotechnology in the past decades \[[@B70-ijms-21-03253]\]. Encapsulation of miRNAs has been mainly carried out using polymers and lipids \[[@B71-ijms-21-03253],[@B72-ijms-21-03253],[@B73-ijms-21-03253]\]. But solid particles such as calcium phosphate have been used as efficient carriers. Often the driving force for the entrapment of negatively charged miRNAs is the electrostatic attraction with cationic lipids or polymers. Physical caging is also another efficient way to entrap miRNAs in empty cavities.

### 5.2.1. Lipidic Nanotherapeutics {#sec5dot2dot1-ijms-21-03253}

Lipofectamine is considered the "gold standard" for nucleic acid transfection. It is a lipid-based nanovector composed of positively charged cationic lipids. Often it is called a "liposome," however it is unclear whether it forms a hollow shell vesicular structure. It has been used extensively to transfect miRNAs and is one of the examples of nanovectors already used to treat PH and other pulmonary diseases. Its high transfection efficiency has been explained by Cardarelli et al. who claimed that these nanoparticles can prevent lysosomal degradation because of their atypical Brownian motion within cells \[[@B74-ijms-21-03253]\]. Other similar commercially available cationic lipid-based vectors are Invivofectamine, NeoFX, or Oligofectamine.

Liposomes are the most advanced and sophisticated delivery systems for miRNA delivery. They are multilamellar or unilamellar spherical vesicles made of phospholipids composed of a hydrophilic head group and a hydrophobic tail. Depending on the chemical nature of the main hydrophilic group, we can differentiate between positive, negative, and neutral charged liposomes. The first generation of liposomes for gene delivery, able to successfully transfect cells, were composed by phospholipids with a positively charged head group \[[@B75-ijms-21-03253]\]. The encapsulation efficiency is enhanced for liposomes with positive charge as compared with negative or neutral liposomes because of the electrostatic attraction with the negatively charged miRNAs. However, the use of permanently charged cationic lipids can induce cellular and inflammatory toxicity, fast plasma clearance, aggregation, and accumulation in lungs, liver, and spleen. The stability, transfection efficiency, and cellular toxicity is determined in a large extend on the lipid composition, so many novel formulations of lipids and liposomes have been developed in the past decades. Ionizable cationic lipids have been chemically designed to produce pH sensitive liposomes able to complex the negatively charged miRNAs at low pH. Interestingly, they shift their charge to neutral charge at physiological pH toward reduced aggregation, toxicity, and electrostatic adherence to cellular membranes. In addition, this charge reversibility triggers a pH-induced release within the acidic endosomal compartments, hypothetically by destabilization of the endosomal membrane because of the electrostatic interaction between the positively charged lipids of liposomes and the negatively charged lipids of the endosomal membrane. Liposomal miR-34a mimics, based on this kind of amphoteric lipids, have successfully entered clinical trials to treat patients with advanced solid tumors \[[@B76-ijms-21-03253]\]. The last advances in liposomal RNA delivery have been assertively reviewed by Peer et al. \[[@B77-ijms-21-03253]\].

### 5.2.2. Polymeric Nanotherapeutics {#sec5dot2dot2-ijms-21-03253}

Using polymers as the building blocks of nanotherapeutics has the advantage of tailoring its sustained and controlled drug delivery properties \[[@B78-ijms-21-03253]\]. Examples of polymers that form complexes with nucleic acids through electrostatic interactions are poly(ethylenimine) or poly(allylamine) \[[@B79-ijms-21-03253]\]. Recently dendrimers, which are highly symmetrical hyperbranched polymers, have also been applied as drug delivery systems for miRNAs. In this case, the encapsulation is due to both hydrophilic and hydrophobic interactions \[[@B80-ijms-21-03253],[@B81-ijms-21-03253]\]. Solid polymeric nanoparticles such as the FDA and EMA-approved poly(lactic-co-glycolic acid) (PLGA) are widely used for sustained drug delivery of hydrophobic drugs encapsulated in the interior. However, they can also entrap inside hydrophilic molecules such as siRNAs or miRNAs applying a double emulsion synthetic method or adsorb them on their surface by electrostatic interactions \[[@B82-ijms-21-03253],[@B83-ijms-21-03253]\]. Many different types of polymeric particles can be applied to entrap and release miRNAs but have not yet been assayed. For example, nanogels are good candidates that have demonstrated decent delivery efficiency for siRNA transfection and would work similarly for miRNA \[[@B84-ijms-21-03253]\]. These nanovectors are crosslinked polymeric networks that have high water content and large mesh size. Its advantage over other possible miRNA carriers is its mild conditions for encapsulation of labile drugs and their stimuli-responsive properties \[[@B85-ijms-21-03253]\].

### 5.2.3. Inorganic Particles as Nanotherapeutics {#sec5dot2dot3-ijms-21-03253}

Inorganic silica and calcium phosphate particles are also promising carriers for miRNA delivery. Both are innocuous to the body and are degraded by hydrolysis, delivering their content. Silica nanoparticles are known for the easy modification of surface chemistry, but also for the variety of sizes, shapes, and structures that can be built with this material. Especially interesting are the porous particles and hollow shells that can host and deliver miRNAs from their hollow cavities \[[@B86-ijms-21-03253],[@B87-ijms-21-03253]\]. Calcium phosphates are among the most widely used pharmaceutical excipients and there are notable examples of miRNAs delivery from this type of particles \[[@B88-ijms-21-03253]\]. They have been even functionalized with targeting moieties for in vivo cell targeting. miRNAs are entrapped in these particles by simple coprecipitation or diffusion under mild conditions \[[@B89-ijms-21-03253]\]. However, they have not yet been applied to pulmonary hypertension.

In this review, we only give a brief summary of the promising nanotherapeutics that could be applied for the encapsulation and delivery of miRNA-based therapies. But often advanced delivery systems are composites. The stealth properties to escape the reticuloendothelial system are obtained mainly by polymer coating (e.g., polyethylene glycol). Targeting can be accomplished by decorating the nanoparticle surface with antibodies, peptides, and other small molecules. And multifunctionality is often sought by combining metallic nanoparticles with other materials such as Nanoplex developed by Wu et al. This miRNA nanovector composed of pH sensitive micelles and superparamagnetic nanoparticles for magnetic resonance imaging was used for combination therapy with two different mimics (miRNA-29b and miRNA-122) against hepatic fibrosis \[[@B90-ijms-21-03253]\]. In conclusion, there is a broad variety of possible drug carriers but it must be assumed that every nanovector has its pros and cons. In this regard, studies such the developed by Osorio et al. comparing the loading, release and therapeutic effect of three different miRNA nanotherapeutics (liposomes, PLGA, and EVs) are of special interest in the field \[[@B91-ijms-21-03253]\].

Although the application of nanotherapies to treat PH is in an early stage, due to the dysfunctional and hyperpermeable vascular endothelium, they could represent a powerful tool to bringing PH therapies, such as miRNAs, to novel cellular targets, as has been assertively reviewed by Segura-Ibarra et al. \[[@B60-ijms-21-03253]\].

6. Administration Routes for Lung Targeting {#sec6-ijms-21-03253}
===========================================

The advantage of targeting lung diseases with miRNA-based therapies as compared with other organs is that it is possible to directly administer these compounds through the respiratory track which limits side and off-target effects \[[@B92-ijms-21-03253]\]. In this context, Scholosser et al. have recently demonstrated that direct administration of mimic miRNA therapeutics via the oronasal or the trachea depositions (with or without aerosolization) are efficient methods for direct targeting of the lungs \[[@B58-ijms-21-03253]\]. In this study, they compared five different direct administration strategies (intratracheal liquid instillation, intratracheal aerosolization with and without ventilator assistance, intranasal liquid instillation, and intranasal aerosolization) with three different systemic strategies used as controls (intravenous, intraperitoneal, and subcutaneous delivery) and demonstrated that all lung-targeted strategies showed lung-selective miRNA mimics uptake as compared to systemic administered mimics. Moreover, they showed that intratracheal administration of a liquid miRNA formulation provided the highest lung specific delivery up to 4 orders of magnitude more than the control strategies. This work highlights the impact of the administration method on the therapeutic outcome and the cost-effectiveness of miRNA mimics.

A second aspect and less advantageous than direct deposition to take into consideration for lung-specific delivery of miRNAs is their elimination by intrinsic pulmonary clearance mechanisms, including enzymatic degradation, quick absorption into the blood, and ingestion by the alveolar macrophages. In this context, nanovector-based delivery systems such as lipid or polymer nanoparticles are used to minimize pulmonary clearance mechanisms, enhance the therapeutic effect, and achieve specific cell targeting \[[@B76-ijms-21-03253]\]. Although cell targeting remains a considerable challenge in nanomedicine, novel and more specialized delivery technologies are continuously being developed, so miRNA technology would benefit from it \[[@B93-ijms-21-03253]\].

7. miRNA-Based Therapies in Pulmonary Diseases {#sec7-ijms-21-03253}
==============================================

Altered expression of miRNAs has been reported for many lung diseases such as asthma, pulmonary fibrosis, and lung cancer \[[@B94-ijms-21-03253]\]. To the best of our knowledge there are no miRNA-based therapies for lung diseases currently accepted by the regulatory agencies, although the same company with patisiran in the market (Ainylam Pharmaceuticals) has finished a phase IIb clinical trial with a siRNA aerosolized therapeutic solution for the treatment of respiratory syncytial virus infection during lung transplantation. Despite this, the promising results obtained in animal models treated with miRNA based therapies have brought great hope in the field \[[@B95-ijms-21-03253]\]. [Table 1](#ijms-21-03253-t001){ref-type="table"} summarizes few of reported miRNA-based therapies for lung diseases emphasizing on the characteristics of the treatment such as the type of treatment, the use of nanovector, the phenotypic effect, and the application.

8. miRNA-Based Therapies in Pulmonary Hypertension {#sec8-ijms-21-03253}
==================================================

Pulmonary hypertension (PH) is a condition characterized by increased mean pulmonary arterial pressure. During the compensatory phase, the right ventricle of the heart deals with pressure overload to maintain the blood flow by chamber transformation. This translates into an adaptive increase in artery wall thickness which involves an uncontrolled cell proliferation. Molecular mechanisms underlying the physiopathology have not been completely elucidated but since there is no cure for this fatal disease it urges to find methodologies for the selective detection and treatment of PH \[[@B100-ijms-21-03253]\]. PH has been classified in five different groups which depend on the origin of the disease. Pulmonary arterial hypertension (PAH) is the commonly the most studied case of PH. In PAH, the small arteries (and in some cases also the venules) in the lung are obstructed due to different reasons such as HIV infection, autoimmune disorders, and others but it can be also idiopathic. All PH groups courses with endothelium dysfunction and vascular remodeling in the lungs which has been extensively described that is accompanied by a metabolic reprogramming in the heart and the lung only explored until recently \[[@B101-ijms-21-03253],[@B102-ijms-21-03253],[@B103-ijms-21-03253]\]. It is known that arterioles can undergo vasoconstriction imbalance, cellular remodeling, thrombosis, and cell proliferation. Pulmonary artery endothelial cells (PAECs), pulmonary artery smooth muscle cells (PASMCs), myofibroblast, pericytes, platelets, and inflammatory cells play key roles during the disease development. The vascular remodeling during PH involves PAECs dysfunction, such as proliferation, interaction with PASMCs, and transdifferentiation and the accumulation of PASMCs in obstructive vascular lesions \[[@B104-ijms-21-03253],[@B105-ijms-21-03253]\]. [Figure 4](#ijms-21-03253-f004){ref-type="fig"} shows schematically a transversal section of a pulmonary artery developing PH.

Currently, PH treatments only help to relieve the symptomatology and do not stop the progression of the disease. The medical therapies available for the treatment of PAH include calcium channel blockers, endothelin receptor antagonists, phosphodiesterase type 5 inhibitors and soluble guanylate cyclase stimulators, prostacyclin analogues, and prostacyclin receptor agonists \[[@B106-ijms-21-03253]\]. miRNA dysregulation has been correlated to the physiopathology of PH and the use of miRNA-based therapies has emerged as new hope toward the reversion of PH symptomatology \[[@B107-ijms-21-03253]\]. [Table 2](#ijms-21-03253-t002){ref-type="table"} summarizes a list of reported miRNA that could be efficient therapeutic targets for the treatment of PH. In many aspects, PH disease development resembles tumorigenesis. In PH and cancer the hyperproliferative and apoptosis resistant phenotype is partially related to impaired mitochondrial dynamics and in both cases there is a metabolic dysfunction (Warburg effect) characterized by a shift from oxidative glucose metabolism to aerobic glycolysis which provides the survival conditions for highly proliferating cells \[[@B17-ijms-21-03253]\]. Given these similarities multiple miRNAs that are aberrantly expressed in cancer are also dysregulated in PH. For instance, miR-204 and miR-205 are downregulated in pulmonary artery small muscle cells (PASMs) in PAH as well as in many cancers \[[@B108-ijms-21-03253]\]. In both cases the downregulation of these miRNAs induces metabolic dysfunction and enhanced PASMCs proliferation. MiR-204 and miR-205-based treatments have demonstrated to be efficient for decreasing cell proliferation and metastasis in few cancers and recently it has been reported their potential use for reversing PAH in a murine model \[[@B109-ijms-21-03253],[@B110-ijms-21-03253]\]. Its encapsulation and targeted release in the lungs could be advantageous for preventing the miRNAs being filtered by the kidney, decrease off-targeted effects, and improve intracellular delivery.

[Table 2](#ijms-21-03253-t002){ref-type="table"} shows a small portion of the possible miRNA targets and some of their reported targeted genes that could be used to treat PH. Considering that only for dysfunctional PAECs more than 20 different dysregulated miRNAs have been already reported, it will become essential to use in silico approaches to identify the most relevant miRNA targets for developing novel treatments against PAH \[[@B126-ijms-21-03253]\]. In this context, we referred readers to the work recently published by Bonnet et al. \[[@B95-ijms-21-03253]\].

Currently, the treatment of PH with miRNA-based therapies is still in an early phase, similar to siRNA-based therapies \[[@B127-ijms-21-03253]\]. There are no clinical trials going on yet, but fortunately all reported pre-clinical trials up to now have shown significant beneficial effects and some of them have demonstrated an evident decrease of the arteriopathy and cardiac dysfunction. We have collected these examples in [Table 3](#ijms-21-03253-t003){ref-type="table"}.

As can be seen in [Table 3](#ijms-21-03253-t003){ref-type="table"}, some studies aimed at determining the possible therapeutic effect of a target miRNA using bare miRNA mimics or Antagomirs as a first assay. This was the case of the study carried out by Pullamsetti et al. in 2012. However, most of the reported research has been done using nanovectors known to improve transfection efficiency such as commercial lipofectamine or viral vectors \[[@B110-ijms-21-03253],[@B130-ijms-21-03253]\]. For instance, in the study of the potential use of miR-145 as a therapeutic target, Caruso et al. was first evidencing the upregulation of miR-145 in humans with PAH and in animal models of PAH. Then, they used antimiR-145 delivered with commercial lipofectamine and showed that it prevented arteriopathy in hypoxic mice. Owing to this study, some years later McLendon et al. reported effective delivery and retention in the lungs of antimiR-145 loaded in more sophisticated cationic liposome-based nanovectors made of polymer-functionalized lipopolyamines that provided stealth properties \[[@B7-ijms-21-03253]\]. Importantly, their results showed an evident decrease of right ventricle pressure, decreased artery muscularization, and lower degree of cardiac dysfunction in murine models of severe PAH while avoiding off-target effects and toxicity. These two last features are essential for the translation of miRNA therapies into clinics but they are still a challenge in the field.

The dose of miRNA required to obtain a therapeutic effect depends on the animal model of PH and many other factors. However, we could draw some general conclusions from [Table 3](#ijms-21-03253-t003){ref-type="table"}. Comparing two different miRNA therapies in mice housed in hypoxic conditions, reduction of arteriopathy could be achieved in both cases after 2--3 intravenous injections per week for 2 weeks (6 injections in total) \[[@B19-ijms-21-03253],[@B128-ijms-21-03253]\]. When miRNAs were not encapsulated, a higher concentration in treatment, 8 mg/Kg as compared with 2 mg/Kg, was required for the administration of Invivofectamine. In rat models with monocrotaline-induced PH or hypoxia and Sugen, the therapeutic effect was achieved only after 2--3 intravenous injections. Similarly, the concentration of miRNA from the injections was lower for encapsulated therapies (2 mg/Kg vs. 5 mg/Kg) \[[@B7-ijms-21-03253],[@B128-ijms-21-03253]\]. The dose could also decrease with direct administration to the lungs, as demonstrated by Courboulin et al. \[[@B109-ijms-21-03253]\]. Only two nebulizations (1 per week) of encapsulated miRNA mimics were required to obtain a therapeutic outcome of miR-204a mimics in a PH model with monocrotaline. This administration method could also avoid some of the potential off-target effects of miRNA-based therapies, but this has not yet been confirmed. Despite the lungs offer the advantage of local delivery of therapies, as can be seen in [Table 3](#ijms-21-03253-t003){ref-type="table"}, the majority of the miRNA treatments are currently being administered intravenously. This is due to the early stage of these therapies and the barriers that still remain for real targeted therapies such as (1) controlling lung clearance, (2) achieving a homogeneous biodistribution, (3) obtaining stable miRNA carriers for nebulization, and (4) obtaining selective delivery systems to the target cells. In addition, what is not yet known is whether the decrease in PH pathology is temporary or lasting \[[@B43-ijms-21-03253]\]. Future advances in other miRNA therapies such as cancer are likely to help address these challenges for PH \[[@B44-ijms-21-03253]\].

In the field of non-coding RNA therapies, combination therapies are expected to be more efficient than single-target RNA; Sindi et al. have obtained outstanding results in this direction already in PH \[[@B19-ijms-21-03253]\]. These authors first focused their work on deciphering whether the Krüppel-like factor 2 (KLF2) signaling pathway in PAECs could be a novel molecular target to combat PH. They then demonstrated that the combination therapy of exosomal miR-181a-5p and miR-324-5p was helpful in reducing right ventricle pressure and hypertrophy, cell proliferation and angiogenesis in murine models. Interestingly, they compared single miRNA delivery with combination therapy displaying a higher efficiency for the latter. This study, in addition shows the potential use of exosomes as efficient carriers for miRNA-based therapies, illustrates perfectly how important is to detect many different miRNAs to find the best therapeutic outcome.

[Figure 5](#ijms-21-03253-f005){ref-type="fig"} depicts the few but promising nanovectors applied to date to treat PH with miRNA therapies and their reported cell targets (also reported in [Table 3](#ijms-21-03253-t003){ref-type="table"}). Nanovectors may target PASMCs because of dysfunctional endothelium patency in HP \[[@B131-ijms-21-03253]\]. However, the use of nanovectors functionalized with targeting molecules could show significant improvements to avoid side and off-target effects while improving therapeutic outcomes. Peptides and antibodies have been already applied successfully in miRNA-based therapies when targeting other organs such as heart or liver \[[@B70-ijms-21-03253],[@B132-ijms-21-03253],[@B133-ijms-21-03253],[@B134-ijms-21-03253]\], so we are convinced that this strategy will be promptly applied in PH treatments. There is plenty of room for improvement in miRNA therapeutics for PH.

9. Conclusions {#sec9-ijms-21-03253}
==============

Although nowadays the majority of miRNA-based therapeutics in clinical trials and patents are related with cancer \[[@B43-ijms-21-03253]\], there is a great promise for the treatment of pulmonary diseases and other pathologies. In particular pulmonary hypertension can greatly benefit from all the research that has been already advanced for miRNA-based cancer treatments. PH and cancer hold many similarities such as cell hyperproliferation and the Warburg effect that make easier to find appropriated molecular targets. We have shown that there is a long list of possible miRNA targets for developing miRNA-based treatments for PH but few studies that have already assayed their efficacy to reverse the severity of this fatal disease. However, they have shown that it is possible to reduce uncontrolled cell proliferation, reduce vascular remodeling and angiogenesis in preclinical trials. This successful early phase research reflects the need of developing robust delivery technologies. Bare miRNAs cell transfection is a very inefficient process that has been ameliorated with chemical modifications of such oligonucleotides. Unlikely, these modifications often decrease their specificity and there is a general consensus about the future role of nanovectors in the advance of the field. Until now, there are no perfect nanovectors for miRNA delivery, but we are convinced that the way to advance this type of therapy will go through the improvement of known nanotherapies, either with increased transfection efficiency, moieties to target cells, or combination therapies. All this will be aimed at improving efficacy and specificity which are currently the main goals for miRNA-loaded nanovectors applied to PH.
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![One of the possible mechanisms and pathways of the miRNA biogenesis within eukaryotic cells of mammals. We have marked with a blue pill drawing and a number 1\* to 4\* the possible miRNA and miRNA precursors that can be targeted for the different therapeutic strategies explained in [Section 4](#sec4-ijms-21-03253){ref-type="sec"}. (\#) Indicates that this pathway can be different.](ijms-21-03253-g001){#ijms-21-03253-f001}

![Complementary binding between mRNA and miRNA at the seed region located on the bases 2--8 on the 5´ end of mature miRNA and the 3´UTR of the target mRNA.](ijms-21-03253-g002){#ijms-21-03253-f002}

![Schematic representation of different nanovectors loaded with miRNA-based therapies. (**1** & **2**) depict an adenovirus and an EDV^TM^ nanocell. (**3**) Depicts a nanovector made of a positively charge polymer and negatively charged miRNA-based therapy. (**4**) Depicts a dendrimer. (**5**) Depicts a multifunctional liposome, loaded in its interior with miRNAs and functionalized with PEG (in red) on its surface and a contrast agent (yellow star) within the lipidic bilayer. (**6**) Depicts a solid nanoparticle coated with a positively charged polymer (in red) and the miRNA-based therapy via self-assembly. (**7**) Depicts a porous solid particle which encapsulates the miRNA-based therapy within its pores and it is coated to seal the pores. Therapeutic miRNA is depicted in blue and polymeric coatings in red.](ijms-21-03253-g003){#ijms-21-03253-f003}

![Schematic drawing of a transversal section of a pulmonary artery developing PH and the structural alterations in the different cellular levels. Initially smooth muscle cells excessively proliferate producing vasoconstriction. After that, inflammation, remodeling, and thrombotic lesions will follow.](ijms-21-03253-g004){#ijms-21-03253-f004}

![Schematic drawing of a cross section of two pulmonary arteries that develop PH and are being treated with nanopharmaceuticals (represented as small red and black spheres) that target the endothelial cells of the PAEC arteries (**A**) or smooth muscle cells PASMC (**B**). Endothelial dysfunction leads to a patent state in which NPs can leak into the pulmonary vasculature and reach PASMC more easily than in healthy arteries. The nanovectors collected in [Table 3](#ijms-21-03253-t003){ref-type="table"} are shown here.](ijms-21-03253-g005){#ijms-21-03253-f005}

ijms-21-03253-t001_Table 1

###### 

Examples of miRNA-based therapies applied in lung diseases.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Targeted miRNA   NV ^1^          Admin. ^2^      Type of Therapy   Disease       Effect                               Application                       Ref. ^3^
  ---------------- --------------- --------------- ----------------- ------------- ------------------------------------ --------------------------------- --------------------------
  miR-29           None            i.v.i. ^4^      Repl. ^5^         PF ^6^        ↓Col1a1 ^7^, Col3a1 ^8^ expression   BMM ^9^                           \[[@B96-ijms-21-03253]\]

  miR-200c         None            int.ins. ^10^   Repl.             PF            ↓ Fibroblast fibrogenic phenotype    BMM\                              \[[@B97-ijms-21-03253]\]
                                                                                                                        Human cells                       

  miR-155-5p       None            intranasal      Inh. ^11^         Asthma        ↓ Disease phenotype                  Allergic airway disease MM ^12^   \[[@B98-ijms-21-03253]\]

  miR-101          Adenovirus      inh.            Repl.             PF            ↓ Fibroblast proliferation           BMM                               \[[@B99-ijms-21-03253]\]

  miR-34a          Lipid NP ^13^   s.c. ^14^       Repl.             Lung cancer   ↓ Tumor growth                       Lung cancer xenograph             \[[@B87-ijms-21-03253]\]

  miR-34a          Liposome        i.v.i.          Repl.             Solid tumor   ↑ Antitumor activity                 Humans, Phase I                   \[[@B76-ijms-21-03253]\]
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^1^ Nanovector. ^2^ Administration. ^3^ Reference. ^4^ Intravenous injection. ^5^ Replacement therapy. ^6^ Pulmonary fibrosis. ^7^ Collagen1a1. ^8^ Collagen3a1. ^9^ Bleomycin murine model. ^10^ Intratracheal instillation. ^11^ Inhibition therapy. ^12^ Murine model. ^13^ Nanoparticle. ^14^ Subcutaneous injection. ↑ means increase and ↓ means decrease.

ijms-21-03253-t002_Table 2

###### 

Reported dysregulated miRNA biomarkers in pulmonary hypertension, origin of the obtained data, reported targets and miR functions.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  miRNA         Model                               Target Gene                       Exp. ^1^   Function                                                                               Ref. ^2^
  ------------- ----------------------------------- --------------------------------- ---------- -------------------------------------------------------------------------------------- ---------------------------
  miR-9-1\      PASMCs ^3^ from HMM ^4^             HIF-1 α                           ↑          Phenotypic switch                                                                      \[[@B111-ijms-21-03253]\]
  + miR-9-3                                                                                                                                                                             

  miR-17-5p\    Bioinformatics +HEK293 cells        BMPR2                             ↑          Differentiation, proliferation and fibrous matrix production of PAECS ^5^ and PASMCs   \[[@B112-ijms-21-03253]\]
  + miR-20a                                                                                                                                                                             

  miR-100       HMM, MCT ^6^                        mTOR                              ↓          Proliferation of PASMCs                                                                \[[@B113-ijms-21-03253]\]

  miR-124       HPAECs ^7^                          PTPB1 + PKM1/M2                   ↓          Proliferation of PASMCs and PAFs ^8^                                                   \[[@B114-ijms-21-03253]\]

  miR-140-5p    Bioinformatics (miRBase database)   23 genes & 7 signaling pathways   ↓          Proliferation and pro-differentiation of PAECS, PASMCs & PAFs                          \[[@B115-ijms-21-03253]\]

  miR-145       HMM, HPASMC                         BMPR2                             ↑          Proliferation of PASMCs                                                                \[[@B116-ijms-21-03253]\]

  miR-199a-5p   HPASMCs, HPAECs & HMM               SMAD3                             ↑          Inhibit the level of NO and promote the concentration of Ca^2+^                        \[[@B117-ijms-21-03253]\]

  miR-204       PAECs                               TGFBR2, α-SMA, SMAD2/7            ↓          Proliferation and migration of PAECs                                                   \[[@B118-ijms-21-03253]\]

  miR-205-5p    Hypoxic PASMCs & HMM                MICAL2\                           ↓          Proliferation of PASMCs                                                                \[[@B110-ijms-21-03253]\]
                                                    ERK1/2 signaling                                                                                                                    

  miR-206       PASMCs & HMM                        HIF-1 α /FHL-1                    ↓          Promotion of cell entry into the S phase and PASMC proliferation                       \[[@B119-ijms-21-03253]\]

  miR-214       Hypoxic HPASMCs, Sugen/HMM          CCNL2, LMOD1, MEF2C, PTEN         ↑          Proliferation of PASMCs by suppressing cell apoptosis                                  \[[@B120-ijms-21-03253]\]

  miR-339       MCT murine model                    FGF                               ↓          Proliferation of PASMC                                                                 \[[@B121-ijms-21-03253]\]

  miR-449a-5p   PASMCs from MCT                     MYC                               ↓          Mitochondrial dysfunction and proliferation of PASMCs                                  \[[@B122-ijms-21-03253]\]

  miR-1281      Hypoxic HPASMCs & MCT               HDAC4                             ↓          Cell proliferation and migration                                                       \[[@B123-ijms-21-03253]\]

  miR-637       HPASMCs                             CDK6                              ↓          Increase PASMCs viability                                                              \[[@B124-ijms-21-03253]\]

  miR-4632      HPASMCs                             JUN                               ↓          Inhibit proliferation and promote HPASMCs apoptosis                                    \[[@B125-ijms-21-03253]\]
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^1^ Expression of miRNA. ^2^ Reference. ^3^ Pulmonary artery smooth muscle cells. ^4^ Hypoxic murine model. ^5^ Pulmonary artery endothelial cells. ^6^ Monocrotaline murine model. ^7^ Human pulmonary artery endothelial cells. ^8^ Pulmonary artery fibroblasts. ↑ means increase and ↓ means decrease.

ijms-21-03253-t003_Table 3

###### 

Relevant information about miRNA-based therapies in pulmonary hypertension.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Targeted miRNA           NV ^1^                   Adm. ^2^        Therapy      Effect                      Application    Target cell   Ref. ^3^
  ------------------------ ------------------------ --------------- ------------ --------------------------- -------------- ------------- ---------------------------
  miR-17\                  None\                    i.v.i. ^4^      Inh. ^5^     ↓Arteriopathy\              MCT ^8^\       PASMC         \[[@B128-ijms-21-03253]\]
                           (Antagomir)                                           ↓RVP ^6^\                   HMM ^9^                      
                                                                                 ↓RVH ^7^\                                                
                                                                                 ↑Artery acceleration time                                

  miR-21                   None\                    i.v.i           Inh.         ↓Arteriopathy\              HMM            PASMC         \[[@B128-ijms-21-03253]\]
                           (Antagomirs)                                          ↓RVP                                                     

  miR-92a                  None\                    i.v.i           Inh.         ↓Arteriopathy               HMM            PASMC         \[[@B128-ijms-21-03253]\]
                           (Antagomirs)                                                                                                   

  miR-17\~92               Lentivirus\              i.v.i.          Repl.        Restore hypoxia phenotype   PASMCs\        PASMC         \[[@B129-ijms-21-03253]\]
                           (+ miR mimics)                                                                    HM-KO-M ^10^                 

  miR-145                  Lipofectamine            s.c.i. ^11^     Inh.         ↓RVP\                       HPASMC\        PASMC         \[[@B116-ijms-21-03253]\]
                                                                                 ↓ Arteriopathy              HMM                          

  miR-145                  Liposomes ^12^           i.v.i.          Inh.         ↓RVP\                       Sugen/HMM      PASMC         \[[@B7-ijms-21-03253]\]
                                                                                 ↓Artery thickness                                        

  miR-181a-5p/miR-324-5p   EV and Invivofectamine   i.v.i           Repl. ^13^   ↓RVP, ↓RVH\                 HPAECs\        PAEC          \[[@B19-ijms-21-03253]\]
                                                                                 ↓Cell proliferation\        Sugen/HMM                    
                                                                                 ↓Angiogenesis                                            

  miR-204a                 Invivofectamine          int.neb. ^14^   Repl.        ↓Cell proliferation\        PASMCs\        PASMC         \[[@B109-ijms-21-03253]\]
                                                                                 ↓Vascular remodeling\       MCT                          
                                                                                 ↓PA blood pressure                                       

  miR-205                  Lipofectamine            in vitro        Repl.        ↓PASMC proliferation        PASMC\         PASMC         \[[@B110-ijms-21-03253]\]
                                                                                                             HPASMC                       

  miR-495                  Adeno-associated virus   i.v.i.          Inh.         ↓Vascular remodeling\       Sugen/HMM      PAEC          \[[@B130-ijms-21-03253]\]
                                                                                 ↓Angiogenesis                                            
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------

^1^ Nanovector. ^2^ Administration. ^3^ Reference. ^4^ Intravenous injection. ^5^ Inhibition therapy. ^6^ Right Ventricle Preassure. ^7^ Right Ventricle Hypertrophy. ^8^ Monocrotaline murine model. ^9^ Hypoxic murine model. ^10^ Hypoxic murine knockout model. ^11^ Subcutaneous injection. ^12^ Nanoparticles. ^13^ Replacement therapy. ^14^ Intratracheal nebulization. ↑ means increase and ↓ means decrease.
